Integral Molecular Secures $8 Million Contract for Virus Research
Integral Molecular, renowned for pioneering innovative technologies in vaccine and therapeutic discovery, has achieved a significant milestone with a five-year, $8 million contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. This funding is directed towards critical research pertaining to emerging viral threats that have the potential to evolve into pandemics. This marks the fourth contract awarded to Integral Molecular over a period of 15 years, demonstrating their consistent leadership in this vital field.
Cutting-Edge Technology and Research
The company plans to leverage its state-of-the-art high-throughput mapping platform to pinpoint antibody binding sites, commonly referred to as epitopes, on various viruses. By characterizing immune responses to these viral threats, Integral Molecular provides crucial information that aids scientists in developing effective vaccines. Integral's innovative Reporter Virus Particles (RVPs) feature prominently in this research. These non-replicative virus particles facilitate safe and efficient neutralization studies of highly pathogenic viruses within standard laboratory conditions. RVPs are extensively utilized globally, contributing to the rapid development of vaccines against significant viral diseases like SARS-CoV-2, Ebola, dengue, and influenza, with over 200 peer-reviewed papers highlighting their influence.
Expanding Focus on Emerging Viruses
The new contract allows Integral Molecular to broaden its research scope to include emerging viral threats such as Rift Valley Fever, Crimean-Congo Hemorrhagic Fever, and Enterovirus D68. Previous efforts have already led to the identification of more than 900 epitopes relevant to the human immune response to these viruses, many of which have been published in prestigious scientific journals such as Cell, Science, and Nature.
Responding to Global Health Needs
"We are grateful to NIAID for their continued support and trust in our capabilities," stated Benjamin Doranz, CEO of Integral Molecular. He emphasized the urgent need for preparedness against unexpected viral outbreaks, stating that this contract empowers the company to enhance pandemic readiness, especially for those viruses that have been overlooked and classified as potential threats. By applying their advanced technologies, Integral Molecular strives to make virology research more accessible to laboratories and institutions worldwide.
Integral Molecular's Role in the Biotech Community
With over 20 years in the industry, Integral Molecular stands at the forefront of biotech research, focusing on membrane proteins, viruses, and antibodies. Their technologies have been integrated into drug discovery processes across more than 600 biotech and pharmaceutical companies, aiding in the development of new treatments for diseases such as cancer, diabetes, and various viral infections, including SARS-CoV-2, Ebola, Zika, and dengue.
Staying Connected with Integral Molecular
Integral Molecular maintains an active presence in the scientific community. Followers can stay updated on the company’s latest developments and contributions to biotechnological enhancements through their social platforms. Integral Molecular also welcomes inquiries and collaborative opportunities, reinforcing their commitment to advancing public health through innovative science.
Frequently Asked Questions
What is the purpose of the NIAID contract?
The NIAID contract provides funding for Integral Molecular to conduct essential research on emerging viral threats, enhancing vaccine development and pandemic preparedness.
What technologies does Integral Molecular use?
Integral Molecular utilizes advanced technologies like high-throughput mapping platforms and Reporter Virus Particles for research on viral epitopes and immune responses.
How long is the contract awarded to Integral Molecular?
The contract awarded to Integral Molecular spans five years, allowing for extensive research into various viral threats.
What are some of the viral threats under research?
Integral Molecular’s research focuses on viral threats including Rift Valley Fever, Crimean-Congo Hemorrhagic Fever, and Enterovirus D68, among others.
How has Integral Molecular contributed to the biotech industry?
With over two decades of expertise, Integral Molecular has helped over 600 biotech and pharmaceutical companies discover new therapies for challenging diseases, integrating their technologies into drug discovery pipelines.
